Section 3 of 6
Product information and disease description
264 evidence topics · 141 sources
Product description
Phase of product development
Regulatory status: Under review; NDA submitted September 2026
Launch
No evidence found.
Investigational status: no approved product
Studies supporting submissions outside the United States and in a second seizure type
FDA expedited program designations, filing acceptance, and action date
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Development history and prior product codes
“Originally described in a patent by Valeant Pharmaceuticals in 2008, azetukalner was acquired by First-Order Pharmaceuticals in 2015 and later obtained by Xenon Pharmaceuticals in 2017. It was formerly known as encukalner, XEN1101, 1OP-2198, or VRX621698” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Therapeutic class: KV7 potassium channel opener
Molecular target and seizure type addressed
Brand name
No evidence found.
Dosage forms and strengths
Oral capsule formulation used in the Phase 2b study
“This was a multicenter, randomized, double-blind, parallel-group, dose-ranging, placebo-controlled adjunctive-therapy clinical trial in which XEN1101 was administered once daily with food as a 10-, 20-, or 25-mg oral capsule.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immediate-release capsules used in Phase 1
Strengths evaluated in the Phase 3 focal seizure studies
Registry record of the dosage form
Average sales price and wholesale acquisition cost
Announced price for azetukalner
No evidence found.
No approved product and no product revenue
Branded adjunctive antiseizure medication comparators: United States National Average Drug Acquisition Cost, week of 16 September 2026
| Product and strength | Quoted record description | Quoted acquisition cost per unit | Quoted effective date |
|---|---|---|---|
| Cenobamate 200 mg tablet | “XCOPRI 200 MG TABLET” | “39.86819” | “2026-08-19” |
| Brivaracetam 100 mg tablet | “BRIVIACT 100 MG TABLET” | “24.07624” | “2026-08-19” |
| Perampanel 12 mg tablet | “FYCOMPA 12 MG TABLET” | “39.07764” | “2026-08-19” |
United States brand and generic antiseizure medication price levels, 2013 to 2023
“This study utilized National Average Drug Acquisition Cost (NADAC) data from November 2013 to July 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From 2013-2016 to 2020-2023, accounting for standard deviations (SD), the average price of brand-name ASMs increased from $8.71 (SD 5.9) to $15.43 (SD 10.7), while generic ASMs saw a slight decrease from $1.39 (SD 1.8) to $1.26 (SD 1.6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Consequently, the price gap between brand-name and generic ASMs surged from 1452.39 % to 3399.26 %.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cenobamate list price, United Kingdom
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
Indication
Indication sought in the United States New Drug Application
Adjunctive use in adults, as studied in the registration trial
Pharmacology
Mechanism of action
Potassium channel opening and neuronal hyperpolarization
In vitro potency at KV7.2 and KV7.2/7.3 channels
“In these systems, azetukalner was found to activate Kv7.2 channels with half-maximal effective concentrations (EC50) of 11 and 15 nM, respectively. In a Xenopus oocyte expression system, azetukalner activated channels Kv7.2, Kv7.5, Kv7.4, and Kv7.2/7.3 heteromer with EC50 values of 0.45, 0.35, 0.63, and 0.35 µM, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subtype selectivity within the KV7 family
“In in vitro studies in CHO cell lines expressing heteromeric Kv7.2/7.3 and Kv7.3/7.5 channels and homomeric Kv7.4 channels, azetukalner showed 3.4-fold greater selectivity for Kv7.2/7.3 over Kv7.3/7.5 and Kv7.4 channels, with EC50 values of 27 nM versus 94 nM and 113 nM, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selectivity over other ion channels and the GABA system
Relative rather than absolute selectivity
“Reported selectivity is subtype-relative rather than absolute: in heterologous expression assays azetukalner is approximately fourfold more potent at KV7.2/7.3 than at KV7.3/7.5 or KV7.4, with screening selectivity over unrelated channels and receptors reported as greater than 100-fold, including absence of the GABAA activity seen with retigabine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Potency relative to ezogabine
“In studies with human embryonic kidney (HEK) cells expressing Kv7.2/7.3 channels, azetukalner (EC50, 42 nM) was 20 times more potent than ezogabine (EC50, 920 nM) in causing an approximate 40 mV leftward (negative) shift in the half-maximal voltage of channel activation, while causing a similar increase in maximal conductance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Structural basis for bypassing the pigment-forming pathway
“It was designed to bypass the pigment-forming pathway associated with retigabine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike retigabine, which bears a secondary aromatic amino group, the amino functionality of azetukalner is incorporated within a tetrahydroisoquinoline ring system, which sterically and electronically constrains the nitrogen atom and prevents 1 from participating in oxidative dimerization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Preclinical antiseizure activity in rodent seizure models
“In the MES test, azetukalner has ED50 values of 1.1 mg/kg in rats at 60 min after per os (p.o.) dosing, and 2.2 mg/kg in mice at 120 min after i.p. dosing. In mice, azetukalner is also effective in protecting against seizures induced by subcutaneous (s.c.) pentylenetetrazole, s.c. picrotoxin, s.c. bicuculline, and 6 Hz stimulation, with ED50 values < 10 mg/kg i.p., which correspond to a > 3–19-fold greater potency compared with ezogabine (Table 2 )” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transcranial magnetic stimulation biomarkers of cortical excitability
“Consistent with previous TMS investigations of antiepileptic drugs (AEDs) targeting ion channels, the amplitude of TEPs occurring at early (15–55 msec after TMS) and at late (150–250 msec after TMS) latencies were significantly suppressed from baseline by 20 mg of XEN1101. Furthermore, the RMT showed a significant time-dependent increase that correlated with the XEN1101 plasma concentration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concentration-effect relationship for resting motor threshold
“Mean plasma azetukalner concentrations (± SD) at 2, 4, and 6 h after dosing were 15.7 ± 21.5 ng/mL, 30.2 ± 21.9 ng/mL, and 42.1 ± 19.1 ng/mL, respectively. At the time of individual peak drug concentrations, plasma azetukalner levels correlated significantly with changes in RMTs, but not with changes in TEPs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Use of the transcranial magnetic stimulation study for target engagement and dose selection
Pharmacokinetics
Absorption and time to peak concentration
“After single doses ranging from 5 to 30 mg (immediate-release capsules) administered in the fasting state, peak plasma azetukalner concentrations are achieved at 3.2–4.5 h on average. Thereafter, the drug concentration declines with a biphasic profile. Azetukalner AUC increases about 1.8-fold after co-administration with food” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect and dose proportionality
“Absorption in the fed state was relatively slow, with peak drug concentrations occurring at 4–6 h after dosing. When azetukalner is administered in the fasting state, exposure is less than dose proportional. However, after 10 days of once-daily (q.d.) dosing with food, exposure increases proportionally with dose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Half-life and steady state
“The half-life of azetukalner is about 1–2 days, which implies a modest (about 25%) peak-to-trough fluctuation in serum drug concentration on a q.d. dosing schedule” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After multiple dosing, azetukalner elimination shows a late terminal phase with an average half-life of 4–10 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Steady state (defined as no statistical difference between trough levels on successive days) is reached after 7–10 days, even though complete steady state is expected to occur after about 3 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Terminal half-life supporting once-daily dosing without titration
“The pharmacokinetic properties of XEN1101, including a long terminal elimination half-life (approximately 10 days), support once-daily oral dosing without the need for titration at initiation of dosing or tapering at termination of dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 1 single- and multiple-ascending-dose results
“Single- and multiple-ascending-dose studies were conducted in healthy volunteers to evaluate PK and tolerability, including an evaluation of food effects. Testing included single doses of 5 mg, 15 mg, 20 mg, and 30 mg, as well as multiple doses of 15 mg once daily for 7 days. Key PK findings revealed peak plasma concentrations (Cmax) of 31.5 ng/mL (20 mg) and 35.5 ng/mL (30 mg), with corresponding half-lives of 41 h and 63.4 h. Elimination followed a biphasic pattern, characterized by a functional half-life of 1–2 days and a terminal half-life exceeding 5 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolism and elimination
“After 10 days of dosing at 25 mg q.d., only 0.01% of the administered dose is excreted in urine as unchanged drug over a 24 h collection period, indicating that azetukalner renal clearance is negligible” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Azetukalner is cleared by CYP3A4-mediated metabolism, with other CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6) playing little or no role” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A major oxidative metabolite detected in plasma at concentrations of approximately 20% of those of the parent drug has been found to be inactive on Kv7 channels after preliminary testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, and boxed warnings
No evidence found.
Absence of tissue discoloration in the Phase 2b study
“No TEAEs of tissue discoloration were reported. Two nonserious TEAEs of urinary retention were reported in the active treatment groups, 1 of which required a dose reduction; both patients continued to receive the study medication with no other changes or interventions, including no need for catheterization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no cardiovascular signals of concern in electrocardiograms or vital signs, no allergic skin rashes, and no deaths in the study. Urinary problems were infrequent and mild; no catheterization was required. Moreover, tissue discoloration was not observed in this limited duration trial nor in an interim analysis of the ongoing 5-year, open-label extension study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Urinary retention during long-term open-label treatment
“Three participants reported urinary retention, 1 reported it as mild and 2 as moderate; no dose changes were made in any case.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serious AEs were infrequent at 12.7%, as were TEAEs related to urinary retention (1.1%), which have been reported with the use of KV7 channel openers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Urinary retention as a possible class effect of KV7 openers
“Urinary retention has been reported in a small minority of patients receiving chronic treatment with ezogabine and azetukalner” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“urinary retention may be considered a class effect of these medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absence of the ophthalmological and pigmentary pattern seen with retigabine
“However, azetukalner lacks the recognizable pattern of drug-induced organ toxicity, specifically the urinary retention and ophthalmological abnormalities (e.g., retinal pigmentation and visual acuity changes), that limited the clinical use of retigabine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absence of the phenazinium dimers implicated in ezogabine pigmentation
Central nervous system adverse events
“The most common (>10%) TEAEs across all XEN1101 dose groups were dizziness (24.6%), somnolence (15.6%), and fatigue (10.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adverse event of confusional state was reported in 4.7% of the treated groups (2.2% receiving 10 mg, 5.9% receiving 20 mg, and 5.3% receiving 25 mg) and in 0.9% of the placebo group. No allergic rashes occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuropsychiatric adverse events observed in the psychiatry studies
Special populations
Adolescents in the generalized tonic-clonic seizure and open-label studies
“A similar trial ( NCT05667142 ) is being conducted in patients with generalized tonic-clonic seizures, assessing doses of 25 mg q.d. (participants aged ≥ 18 years) and 15 mg or 25 mg q.d (participants aged from 12 to < 18 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age eligibility in the Phase 3 open-label extension
Negligible renal elimination
“After 10 days of dosing at 25 mg q.d., only 0.01% of the administered dose is excreted in urine as unchanged drug over a 24 h collection period, indicating that azetukalner renal clearance is negligible” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic impairment, renal impairment, pregnancy, and lactation
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Azetukalner
CYP3A4 inhibition: itraconazole
“In healthy subjects, a single 400 mg oral dose of the CYP3A4 inhibitor itraconazole given after 10 days of treatment with azetukalner (20 mg q.d.) was associated with an approximately 10% increase in peak plasma azetukalner concentration and a < 30% increase in azetukalner exposure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Longer treatment with itraconazole, however, would be required to adequately assess the effect of CYP3A4 inhibition on azetukalner pharmacokinetics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modelled effect of CYP3A4 inhibitors and inducers
“Modeling pharmacokinetic data from the phase 2b efficacy and safety study (see below) predicted a 32% increase in steady-state plasma azetukalner levels in the presence of CYP3A4 inhibitors. The same model predicted a 22% decrease in azetukalner exposure in the presence of concomitant treatment with a single CYP3A4 inducer, and a 39% decrease in the presence of two or more CYP3A4 inducers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enzyme-inducing antiseizure medications and trial stratification
“Azetukalner is primarily metabolized by cytochrome P450 3A4 (CYP3A4), with minimal involvement from other cytochrome P450 enzymes, and plasma levels of azetukalner may decrease in the presence of CYP3A4 inducers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomization stratified by enzyme-inducing background medication
“XEN1101 is primarily metabolized by cytochrome P450 3A4 isozyme (CYP3A4) without substantial involvement of other CYPs, and plasma levels of XEN1101 may decrease in the presence of CYP3A4 inducers. To ensure balanced distribution across groups, randomization was stratified by background use of CYP3A4 inducer medications (eg, carbamazepine, eslicarbazepine acetate, oxcarbazepine, phenytoin, topiramate, or phenobarbital).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effects of Azetukalner on other drugs
In vitro cytochrome P450 inhibition and induction
“At in vitro concentrations of 3 μmol/L, which are much higher than those anticipated to be clinically efficacious, azetukalner did not cause direct inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, nor did it cause time-dependent inhibition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, no clinically meaningful induction of the pregnane X nuclear receptor (PXR), which is associated with CYP3A4 expression levels, was observed at azetukalner concentrations of 0.1–1 μmol/L” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Low potential for drug interactions in clinical use
“A mechanism of action that differs from that of currently marketed ASMs and a low potential for drug–drug interactions make azetukalner a good candidate for adjunctive therapy in focal-seizure patients receiving any type of concomitant medication. Additional advantages include the feasibility of once daily dosing without titration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No dose adjustment of concomitant antiseizure medications
Effect on hormonal contraceptives
No evidence found.
Dosing and administration
Dosage
Doses evaluated in the Phase 3 focal seizure studies
No titration at initiation or tapering at discontinuation
“Patients were randomized 2:1:1:2 to receive XEN1101, 25, 20, or 10 mg, or placebo with food once daily for 8 weeks. Dosage titration was not used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which enables gradual self-titration associated with a rapid onset of effect, with nearly the maximum seizure reduction achieved in each arm by the first week of treatment, which was sustained throughout the 8-week DBP in the 20- and 25-mg groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose used in long-term open-label treatment
“Participants who completed the DBP with a minimum of 80% study medication compliance and no important protocol deviations were eligible to enter the OLE phase, during which participants from all DBP arms began treatment with azetukalner 20 mg taken once daily with food (Figure 1 ). Azetukalner dose adjustments and changes in concomitant ASMs were allowed during the OLE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration
Oral once-daily administration with food
Rationale for administration with food and timing of the dose
“XEN1101 was administered as a once-daily adjunctive treatment in capsule formulation by mouth. Because the oral bioavailability of XEN1101 is enhanced by coadministration with food, patients were instructed to take the study medication with the evening meal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Access and distribution
Absence of an existing commercial and distribution infrastructure
Reliance on contract manufacturers for commercial supply
Co-prescribed/Concomitant therapies
Adjunctive use on a background of one to three antiseizure medications
Concomitant antiseizure medication use in the Phase 3 trial population
Concomitant antiseizure medication use in the Phase 2b trial population
“A total of 8.9% of the patients received 1 stable ASM at baseline and concomitantly throughout the DBP of the study, 40.6% of the patients received 2, and 50.5% of the patients received 3. Patients had tried and stopped a median of 6 previous ASMs before study entry. More than half of the patients (57.8%) were taking a CYP3A4 inducer at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Polytherapy in routine epilepsy management
Rationale for combining distinct mechanisms of action
Effect of Azetukalner on quality measures
No evidence found.
Product comparison
Comparison with ezogabine: potency and daily dose
Comparison with retigabine: daily dose and metabolic burden
“This is evident in the contrasting profiles of retigabine (600–1200 mg/day) and azetukalner (25 mg/day), where the significantly lower dose of azetukalner may reduce the burden on detoxification pathways.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison with ezogabine: dosing schedule and tolerability limits of the predecessor
“Ezogabine was approved for the treatment of focal seizures in 2011 but, because of the risk of pigmentary changes affecting the retina and the skin, and the consequent need for intensive ophthalmological monitoring, it was never used widely.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One factor that probably contributed to ezogabine suboptimal tolerability was its short half-life, which results in considerable fluctuations in serum drug concentrations at steady state. The need for a t.i.d. regimen limited its acceptability in the clinical setting, and retention on treatment was generally lower than that reported for other second-generation ASMs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison with retigabine: metabolic stability and brain penetration
Comparison with currently marketed antiseizure medications: confusional state
“The most frequent TEAEs (dizziness, balance disorder, dysarthria, and gait disturbance) were related to the central nervous system and were similar to those associated with other commonly used ASMs. Some of these TEAEs were dose related and occurred at the highest dose. The adverse event of confusional state occurred at an overall rate of 4.7% in the treated group, which was 3.8% higher than placebo. These rates are similar to the frequencies of the rates observed in placebo-controlled phase 3 trials of lacosamide and oxcarbazepine, and less than the rates in trials of eslicarbazepine, pregabalin, perampanel, and topiramate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanistic position relative to the available treatment armamentarium
Comparison with other potassium channel modulators in development
“Related developments include BHV-7000 (BNP-25203), a KV7.2/7.3 modulator in phase II/III for both KCNQ2-DEE (precision use) and focal epilepsy; XEN496, a pediatric retigabine formulation repurposed as precision therapy for KCNQ2-DEE; and AUT-00206, a KV3.1/3.2 modulator in phase II for fragile X syndrome that enhances cortical network synchronization consistent with restored parvalbumin-interneuron function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct comparison with another active antiseizure medication
No evidence found.
Place of product in therapy
Disease description
Definition and etiology
Operational definition of epilepsy
“Seizures are defined as transient symptoms and signs due to abnormal excessive or simultaneous neuronal activity of a population of neuronal cells in the brain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The diagnosis of epilepsy requires at least two unprovoked seizures occurring greater than twenty-four hours apart.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, the definition of epilepsy has been revised and expanded from having two or more unprovoked seizures more than twenty-four hours apart to including those with one seizure and a high likelihood (more than 60%) of having another” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than 60% was taken because it is the lower limit of the confidence interval for the individual with two unprovoked seizures having another seizure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resolved epilepsy
Definition of focal seizures and the seizure classes
“Focal seizures are defined as originating within networks limited to one hemisphere.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They may be discretely localized or more widely distributed and may originate in cortical or subcortical structures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The updated classification maintains four main seizure classes: Focal, Generalized, Unknown (whether focal or generalized), and Unclassified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This updated classification comprises four main classes and 21 seizure types.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition of drug-resistant epilepsy
“Failure of adequate trials of two tolerated and appropriately chosen and used antiseizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of people for whom treatment fails to control their seizures remains at about 30%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predictors of drug resistance and its association with focal epilepsy
“Some syndromes respond better to medication, e.g. the idiopathic generalized epilepsies or the childhood onset self-limited epilepsies which are less associated with resistance than the focal epilepsies or most of the DEEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The two most robust epidemiological predictors of resistance are the number of previous ASMs tried (irrespective of the class of medication) and the number of seizures prior to starting medication, which is more likely a measure of disease severity rather than seizures influencing drug response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age distribution of etiologies
Epidemiology
Incidence of Focal onset seizures
Incidence of focal compared with generalized seizures
“Focal seizures are more common than generalized seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median focal seizure incidence rate is 30.4 per 100,000 per year, compared to 19.6 per 100,000 per year for generalized seizures” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common type of focal seizures are focal impaired awareness seizures, accounting for approximately a third of all cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated incidence of epilepsy among European adults
“Epilepsy has an unequal distribution” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the age-specific incidence rates in European studies, the estimated number of new cases per year among European adults aged 20−64 is 960,000 (incidence rate 30 per 100,000) and 85,000 in the ≥ 65 years population (incidence 100 per 100,000)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of the epilepsy population with focal epilepsy
Prevalence of Focal onset seizures
United States prevalence of active epilepsy, 2015
“In 2015, 1.2% of the U.S. population (3.4 million persons: 3 million adults and 470,000 children) reported active epilepsy (self-reported doctor-diagnosed epilepsy and under treatment or with recent seizures within 12 months of interview) or current epilepsy (parent-reported doctor-diagnosed epilepsy and current epilepsy).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States prevalence of active epilepsy among adults, 2021
Treated prevalence of epilepsy and seizures in the United States, 2010 to 2018
Global prevalence of active epilepsy
“In 2016, there were 45·9 million (95% UI 39·9–54·6) patients with all-active epilepsy (both idiopathic and secondary epilepsy globally; age-standardised prevalence 621·5 per 100 000 population; 540·1–737·0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalence of active epilepsy increased with age, with peaks at 5–9 years (374·8 [280·1–490·0]) and at older than 80 years of age (545·1 [444·2–652·0]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of prevalent epilepsy that is focal
“The prevalence of focal epilepsy was 3.70 per 1000, accounting for 61% of epilepsy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, estimates in 2016 for France, Germany, Italy, Spain, and the UK show that two-thirds of people with epilepsy had focal seizures, equating to over 1.3 million people” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of people with epilepsy who are drug resistant
Persistent seizures among United States adults with focal epilepsy
Natural history, survival, and mortality
Standardized mortality ratios in epilepsy
“All of these nine showed significant elevations of their SMRs ranging from 1.6 to 3.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among six of these population-based studies representing incidence cohorts including all ages, the weighted median SMR was 2.3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Standard mortality ratios are especially high among people with epilepsy aged <50 years, among those whose epilepsy is categorized as structural/metabolic, those whose seizures do not fully remit under treatment, and those with convulsive seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among deaths directly attributable to epilepsy or seizures, important immediate causes include sudden unexpected death in epilepsy (SUDEP), status epilepticus, unintentional injuries, and suicide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incidence of sudden unexpected death in epilepsy
“SUDEP risk in children with epilepsy (aged 0–17 years) is 0.22/1,000 patient-years (95% CI 0.16–0.31) (high confidence in evidence). SUDEP risk increases in adults to 1.2/1,000 patient-years (95% CI 0.64–2.32) (low confidence in evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The major risk factor for SUDEP is the occurrence of generalized tonic-clonic seizures (GTCS); the SUDEP risk increases in association with increasing frequency of GTCS occurrence (high confidence in evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should inform adult patients with epilepsy that SUDEP typically affects 1 in 1,000 adults with epilepsy per year; therefore, annually 999 of 1,000 adults will not be affected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should inform persons with epilepsy that seizure freedom, particularly freedom from GTCS, is strongly associated with decreased SUDEP risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sudden unexpected death in epilepsy in treatment-resistant populations
“Nine clinic-based studies, mainly representing people with treatment-resistant epilepsy, yielded higher estimates of SUDEP occurrence, ranging from 1.2 to 6.3 cases of SUDEP annually per 1,000 individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality by seizure control status in drug-resistant focal epilepsy
“An Austrian study found that the standardized mortality ratio for those not seizure free was 3.3 (95% CI 2.6−4.4) compared to 1.4 (95% CI 0.8−2.3) for those seizure free 2 years after diagnosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinic-based studies report an estimate of SUDEP in people with drug-resistant focal epilepsy of up to 6.3 per 1000 people” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“People with epilepsy are at a 27-fold higher risk of sudden death than controls, but this falls to a 16-fold risk when adjusted for sex, comorbidities, and the Charlson comorbidity score” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seizure-related injury, drowning, and suicide
“An observational study of people with epilepsy and convulsive seizures found that ∼60% of the population experienced at least one accidental injury associated with convulsions over 12 months; common injuries in this population included head injuries (35.5%), dental injuries (4.9%), and burns (4.9%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of drowning is also higher in people with epilepsy, with an estimated relative risk ranging from 13- to 19-fold” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attempted and completed suicides are estimated to occur in 5−14.3% of people with epilepsy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the suicide-specific standardized mortality ratio among those with epilepsy is estimated to be 3.3 (95% CI: 2.8−3.7)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global mortality attributable to idiopathic epilepsy
“Global age-standardised mortality rates of idiopathic epilepsy were 1·74 per 100 000 population (1·64–1·87; 1·40 per 100 000 population [1·23–1·54] for women and 2·09 per 100 000 population [1·96–2·25] for men).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Neuronal hyperexcitability and epileptogenesis
“Epilepsy represents a condition in which abnormal neuronal discharges or the hyperexcitability of neurons occur with synchronicity, presenting a significant public health challenge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This transformation presupposes the hyperexcitability of neuron groups, which become prone to discharge abnormally” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epileptiform synchronization in focal epileptic disorders
“Intracellular recordings from neurons located in these foci demonstrated that interictal events were associated with paroxysmal depolarizing shifts (PDSs) of the neuron membrane potential causing bursts of action potential firing followed by a hyperpolarization” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings provide insights into the mechanisms of seizure initiation and maintenance, thus leading to the development of specific pharmacological treatments for focal epileptic disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excitatory signaling in temporal lobe seizure generation
KV7 channels and the M-current in the control of neuronal excitability
“Neuronal Kv7 channels underlie a voltage-gated non-inactivating potassium current known as the M-current.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to its particular characteristics, Kv7 channels show pronounced control over the excitability of neurons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kv7 channels locate to key areas for the control of action potential initiation and propagation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, we will discuss the contribution of altered Kv7 activity to pathologies such as epilepsy and cognitive deficits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Role and yield of routine electroencephalography
“The electroencephalogram (EEG) is the most direct measure of electrical brain activity and the most specific test for the evaluation of epilepsy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients most commonly receive a 20 min routine EEG recorded from 19 scalp electrodes placed according to the 10–20 electrode placement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies show that the initial routine EEG fails to record IEDs in approximately 47–50% of epileptic patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To improve the yield of EEG, subsequent EEG recording should include sleep deprivation, sleep recording, prolonged hyperventilation, optimized light stimulation, addition of an inferior temporal electrode chain, extended EEG duration, and continuous video-EEG monitoring, all measures known to activate IEDs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Classification of focal seizures by state of consciousness
“Focal seizures and those of unknown origin are further classified by the patient’s state of consciousness (impaired or preserved) during the seizure, defined operationally through clinical assessment of awareness and responsiveness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the state of consciousness is undetermined, the seizure is classified under the parent term, that is, the main seizure class (focal seizure or seizure of unknown origin).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consciousness is used as a classifier instead of awareness, with consciousness operationally defined by awareness and responsiveness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consistency of ictal onset in focal seizures
Review of the diagnosis when seizures continue
Assessments that trigger referral to a tertiary epilepsy service
Investigations used to classify seizure type and epilepsy type
Clinical presentation - signs and symptoms
Seizure semiology: focal aware and focal impaired awareness seizures
“Temporal lobe epilepsy (TLE) is the commonest form of focal epilepsy and represents almost 2/3 of cases of intractable epilepsy managed surgically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seizure auras occur in many TLE patients and often exhibit features that are relatively specific for TLE but few are of lateralizing value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Automatisms represent coordinated involuntary motor activity that is stereotyped and virtually always accompanied by altered consciousness and subsequent amnesia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Automatisms occur in almost two thirds of CPSs of mesial temporal lobe onset” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seizure semiology: focal to bilateral tonic-clonic seizures
Seizure semiology: ictal and postictal amnesia
“Individuals with CPSs may be unaware that they had a seizure minutes earlier. They may also be unable to recall events which occurred before seizure onset. The degree of retrograde and anterograde amnesia is variable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Postictal amnesia likely results from bilateral impairment of hippocampal function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive symptoms: memory, executive function, and language impairment
“The proportion with generalized cognitive impairment, another unexpected phenotype for a focal epilepsy, ranged from 15–44% (mean 29%), and the remaining individuals exhibited more focal cognitive patterns, involving reduced executive function and/or speed, and memory and/or language impairments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive symptoms: effect of seizures and medication on learning and memory
“Aside from severe learning disabilities, epilepsy can impact learning through memory impairment. Seizures can reduce alertness and interfere with short-term information storage. Frequent uncontrolled or night-time seizures can impair new information learning, disrupt memory consolidation, and affect language function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cognitive impairments, such as learning difficulties, behavior change, and memory impairment, can be induced or exacerbated by ASMs, particularly those with impaired cognition, depending on dose and individual susceptibility” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric symptoms: mood and anxiety disorders in newly diagnosed focal epilepsy
“A total of 151 (43.5%) patients had a psychiatric diagnosis; 134 (38.6%) met the criteria for a mood and/or anxiety disorder, and 75 (21.6%) reported suicidal ideation with or without attempts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mood (23.6%) and anxiety (27.4%) disorders had comparable prevalence rates, whereas both disorders occurred together in 43 patients (12.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with newly diagnosed focal epilepsy, the prevalence of mood, anxiety disorders, and suicidality is higher than in the general population and comparable to those of patients with established epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric symptoms: pooled prevalence of depression in epilepsy
“Nine studies reported on 29,891 PWE who had an overall prevalence of active (current or past-year) depression of 23.1% (95% confidence interval [CI] 20.6%–28.31%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five of the 14 studies reported on 1,217,024 participants with an overall OR of active depression of 2.77 (95% CI 2.09–3.67) in PWE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric symptoms: other psychiatric comorbidity
“The most prevalent psychiatric comorbidities are depression (23.1%) and anxiety (20.2%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“People with epilepsy may also present with alcohol abuse (8.7%), drug abuse (7.8%), and interictal psychosis (5.2%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Comorbidity burden in adults with active epilepsy
“Approximately 50% of adults with active epilepsy have one or more comorbid conditions, with several conditions, such as depression, anxiety, dementia, migraine, heart disease, peptic ulcers, and arthritis being eight times more common in people with epilepsy compared to the general population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among people with intellectual disability, approximately one in five will also have epilepsy, with prevalence increasing with increasing severity of the intellectual disability” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accelerated brain ageing and cognitive decline in drug-resistant epilepsy
“A study found that people with DRE presented a difference between predicted brain age and chronological age that was on average 4.5 years older than healthy controls” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DRE is related to cognitive decline, and this phenomenon has been conceptualized as accelerated cognitive ageing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seizure-related injury in refractory focal epilepsy
“Another US study found that hospitalization and pharmacy costs in people with focal seizures were twice as high in the refractory cohort versus the nonrefractory cohort. This was mainly due to the higher prevalence of injuries, including fractures, sprains and strains, and wounds” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“People may injure themselves during a seizure resulting in fractures, head injury, sprains, and open wounds” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Employment and unemployment
“Unemployment and underemployment are markedly more common in PwE compared with the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unemployment rates range from similar to twice or three times the rates of the general population, depending on the countries and years examined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Developing specific legislation and programs to include PwE in the workplace could help their social integration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unemployment in drug-resistant focal seizures
“Among people with drug-resistant focal seizures in Europe, high unemployment rates have been shown compared to a matched control population (46% vs. 19%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Productivity loss and unemployment among people with epilepsy are the primary sources of the individual and societal burden” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Driving restrictions
“This consensus statement recommends that in order to be able to drive PWE should have a SFI of at least 3 months, but PWE with focal aware seizures, consistent and prolonged auras, or nocturnal seizures may still drive on a case-by-case basis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to unique state laws and variable physician awareness regarding these, patients may receive the wrong advice regarding driving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Focal onset seizures
Humanistic burden and health-related quality of life
Instruments used to measure health-related quality of life in focal epilepsy
“Ten instruments evaluating HRQOL in people with focal epilepsy were identified, of which four were epilepsy-specific” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HRQOL was also worse, often significantly so, in people with epilepsy and psychiatric disorders, particularly depression, than in those without psychiatric disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life by treatment response in focal epilepsy
| Population | Quoted mean QOLIE-31-P total score with standard deviation |
|---|---|
| Focal epilepsy, drug resistant (n = 184) | “56.4 (18.7)”View highlighted excerpt for this quote |
| Focal epilepsy, drug responsive (n = 53) | “70.8 (13.3)”View highlighted excerpt for this quote |
| Comparison of the two groups | “<0.0001”View highlighted excerpt for this quote |
Stigma
“Almost one quarter (23.8%) of people with epilepsy reported having felt enacted stigma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stigma was associated with family and social support and employment; with increasing perceptions of stigma associated with worse family functioning or unemployment/low employability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Perceived stigma was experienced similarly by both people with epilepsy and their caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seizure freedom and quality of life
“People seizure-free for more than 1 year have a significantly higher preference-based HRQoL than those in any other seizure frequency group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further differentiation of QoL at higher response levels has been reported, with people achieving high response rates (particularly ≥90%) exhibiting higher QoL than people with ≤50% response rates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This suggests that for a significant QoL improvement, seizure freedom must be attained and maintained” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Determinants of reduced quality of life
“Some risk factors for reduced QoL have been identified, including frequent seizures, longer seizure duration, convulsions, and earlier age of onset” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other factors affecting QoL include ASM side effects, depression or anxiety, lack of social support, stigma, and employment concerns” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adults with epilepsy are likely to report more mentally and physically unhealthy days per month than those without epilepsy, with the highest rates in those with seizures in the past 3 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health utilities by seizure frequency in United States adults with focal epilepsy
| Seizure frequency group, United States, unadjusted | Quoted mean SF-6D health utility with standard deviation |
|---|---|
| Total sample (n = 345) | “0.67 ± 0.14”View highlighted excerpt for this quote |
| At least once a week (n = 55) | “0.63 ± 0.14”View highlighted excerpt for this quote |
| One to three times a month (n = 68) | “0.65 ± 0.15”View highlighted excerpt for this quote |
| One to four times a year (n = 71) | “0.67 ± 0.13”View highlighted excerpt for this quote |
| Less than once a year (n = 151) | “0.70 ± 0.14”View highlighted excerpt for this quote |
| p value for relationship to seizure frequency | “0.006”View highlighted excerpt for this quote |
Economic burden and healthcare resource utilization
United States aggregate spending attributable to epilepsy and seizures
“The difference in annual spending for cases compared to controls was $4580 (95% CI = $3362–$5798) for epilepsy, $7935 (95% CI, $6237–$9634) for seizure, and $6853 (95% CI = $5623–$8084) for epilepsy or seizure, translating into aggregate costs of $5.4 billion, $19.0 billion, and $24.5 billion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From 2010 to 2018, the annual growth rate in total spending incurred for seizures and/or epilepsies was 7.6% compared to 3.6% among controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“US economic burden of seizures and/or epilepsies is substantial and warrants interventions focused on their unique and overlapping causes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States spending for adults with epilepsy, 2016 to 2022
“An estimated 6.6 million adults had unclassified seizures, with annual healthcare spending totaling $38.9 billion, substantially more than $21.3 billion for 4.5 million adults with epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adults with unclassified seizures and epilepsy represent a high-need population with great healthcare use and costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of discrete epilepsy-related health care encounters in the United States
“More than 160,000 epilepsy-related emergency transportations, 225,000 emergency department (ED) visits, 49,000 hospitalizations, 700 urgent care visits, and ~2.5 million office visits were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“37.4% of epilepsy-related hospitalizations included care in the intensive care unit (ICU).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In commercially insured patients, epilepsy-related health care encounters had median health plan-paid costs of $22,305 (Q1-Q3 = $14,336–$36,096, hospitalization); $3,375 ($565–$9,095, ICU visit); $1,913 ($417–$4,163, ED visit); $687 ($415–$1,083, emergency transportation); $95 ($23–$232, office visit); and $57 ($0–$171, urgent care visit).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct costs by seizure frequency in United States adults with focal epilepsy
| Seizure frequency group, United States, adjusted least-squares means | Quoted total direct costs in dollars with confidence interval |
|---|---|
| At least one seizure per week | “43,708 (28,420, 67,219)”View highlighted excerpt for this quote |
| One to three seizures per month | “28,978 (19,665, 42,701)”View highlighted excerpt for this quote |
| One to four seizures per year | “20,943 (14,497, 30,257)”View highlighted excerpt for this quote |
| Less than one seizure per year | “18,600 (14,319, 24,162)”View highlighted excerpt for this quote |
| Overall p value | “0.0008”View highlighted excerpt for this quote |
Association of seizure frequency with resource utilization in the United States
“In the United States, seizure frequency was associated with hospitalizations, indirect costs (ages 18–60), and total direct costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results support the hypothesis that reducing seizures can improve productivity and reduce resource utilization and associated costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incremental utilization and cost of uncontrolled and drug-resistant epilepsy
“a US-based study estimated the odds of epilepsy-related hospitalization (OR: 2.2) and epilepsy-related emergency department visits (OR: 1.9) to be more significant for people with uncontrolled epilepsy; epilepsy-related costs were found to be ∼$6890/case/year higher for DRE” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cost of epilepsy depends on seizure severity, frequency, and drug refractoriness (20% to 40% of people with drug-refractory epilepsy account for 80% of the costs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DRE incurs significantly higher resource utilization and costs than controlled epilepsy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall direct cost of epilepsy in the United States
Economic impact of Focal onset seizures on families
Caregiver health care costs and absenteeism in focal onset seizures
“Sick days were significantly lower in the monotherapy cohort (2.4 days vs 4.4 days annually; P <.0001), with an associated cost difference of $541.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers of patients with partial-onset seizures in the adjunctive therapy cohort had significantly greater medical and sick day costs than caregivers in the monotherapy cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings suggest that higher treatment burden among patients with epilepsy is associated with greater direct and indirect healthcare costs for their caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver work loss by treatment regimen
“A 2018 study found that caregivers of people on monotherapy had an average of 2.7 days of work lost annually due to sick leave and short-term disability. In contrast, the caregivers to those on adjunctive therapy had an average of 5.1 days of work lost annually due to the same reasons” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sick leave in caregivers of those on monotherapy was associated with average costs of $582; whereas, in the adjunctive therapy caregivers group, this increased to $1123.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiving time and caregiver distress
“In a 2014 study in which 92% of people had focal seizures, a higher caregiver burden was associated with the individuals taking a higher number of ASMs, lower neuropsychological performance, lower QoL score, and lower caregiver education level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, 11.4 (±21.2) h were spent on care per week, with the majority (58.3%) of caregivers being a spouse/partner” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers of adults with epilepsy experience extreme psychological distress and poor QoL” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results suggest that 72% of caregivers strongly agree that they fear another seizure, irrespective of when the last episode was.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver productivity loss and health-related quality of life
“Caregivers similarly reported high productivity loss and absenteeism related to caregiving duties.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In another international cross-sectional study of caregivers of adults with uncontrolled drug-resistant focal-onset seizures, caregivers reported the greatest problems (moderate, severe, or extreme problems) in anxiety/depression (44% of caregivers) and pain/discomfort (40%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Comparative cost of ambulatory electroencephalography and inpatient video-electroencephalography monitoring
“In a large retrospective cohort study of 13,958 patients, outpatient AEEG cost was significantly lower compared to inpatient VEM monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings were similar to original economic models which indicated that AEEG was up to 66% cheaper than inpatient VEM” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since January 1, 2020, in the United States, reimbursement for long-term inpatient EEG monitoring modified the fee structure for VEM and AEEG reimbursement for professional and technical components” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care utilization before and after seizure monitoring unit admission, Canadian cohort
“A total of 315 of 600 (53%) patients met eligibility criteria. Mean age was 40 years (SD = 17.4), 176 (56%) were female, 220 (70%) had focal epilepsy, and 60 (19%) had functional seizures or physiologic seizure mimics without epilepsy as adjudicated by the attending physician at the point of discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Admission to an SMU is associated with significant and enduring declines in HCU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic uncertainty as a cost driver
“These findings highlight the impact of diagnostic uncertainty and care fragmentation, suggesting that improved identification and healthcare coordination could enhance outcomes and reduce inefficiencies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Sodium channel blockers
Second-line and third-line monotherapy
Initial monotherapy in new-onset adult focal epilepsy
“Lamotrigine (LTG) should (Level B) and levetiracetam (LEV) and zonisamide (ZNS) may (Level C) be considered in decreasing seizure frequency in adults with new-onset focal epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LTG should (Level B) and gabapentin (GBP) may (Level C) be considered in decreasing seizure frequency in patients ≥60 years with new-onset focal epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive sodium channel blockers in treatment-resistant focal epilepsy
“Lacosamide, eslicarbazepine, and extended-release topiramate use should also be considered to decrease seizure frequency in this population (Level B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eslicarbazepine use may be considered to decrease seizure frequency as monotherapy for TRAFE (Level C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Evidence levels for initial monotherapy for adult focal seizures
Lamotrigine compared with levetiracetam and zonisamide in newly diagnosed focal epilepsy
“Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission versus lamotrigine (HR 1·18; 97·5% CI 0·95–1·47)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings do not support the use of levetiracetam or zonisamide as first-line treatments for patients with focal epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lamotrigine should remain a first-line treatment for patients with focal epilepsy and should be the standard treatment in future trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse reactions were reported by 108 (33%) participants who started lamotrigine, 144 (44%) participants who started levetiracetam, and 146 (45%) participants who started zonisamide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanistic basis of the sodium channel blocking class
“Classical ASMs such as phenytoin, carbamazepine, oxcarbazepine (OXC), and lamotrigine preferentially bind to sodium channels in the inactivated state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enhancement of slow inactivation of sodium channels by newer ASMs, such as lacosamide (LCM) and eslicarbazepine acetate (ESL), represents an innovative mechanism distinguishing them from classical VGSC blockers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive lacosamide: pooled efficacy and withdrawal
“The RR for a 50% or greater reduction in seizure frequency for all doses of lacosamide compared with placebo was 1.79 (95% CI 1.55 to 2.08; 5 studies; 2199 participants; high-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The RR for seizure freedom for all doses of lacosamide compared with placebo was 2.27 (95% CI 1.35 to 3.83; 5 studies; 2199 participants; low-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The RR for treatment withdrawal for all doses of lacosamide compared with placebo was 1.57 (95% CI 1.24 to 1.98; 5 studies; 2199 participants; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive lacosamide: pivotal trial
“Median percent reductions in seizure frequency per 28 days from baseline to maintenance (intention-to-treat, ITT) were 37.3% for lacosamide 400 mg/day (p = 0.008) and 37.8% for lacosamide 600 mg/day (p = 0.006) compared to 20.8% for placebo, with responder rates of 38.3% and 41.2%, respectively, compared to placebo (18.3%, p < 0.001; ITT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive lacosamide: seizure freedom in pooled trials
“A total of 2.7%, 3.3% and 4.8% of patients completing the Maintenance Phase in the lacosamide 200, 400 and 600 mg/day groups, respectively, experienced no seizures throughout the entire Maintenance Phase (placebo group = 0.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive eslicarbazepine acetate: pooled efficacy
“For adults, the RR was 1.71 (95% CI 1.42 to 2.05; 5 studies, 1799 participants; moderate-certainty evidence)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESL was associated with seizure freedom (RR 3.16, 95% CI 1.73 to 5.78; 6 studies, 1922 participants; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESL reduces seizure frequency when used as an add-on treatment for adults with drug-resistant focal epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive eslicarbazepine acetate: pivotal trial responder rate
“Responder rate (≥50% reduction in SSF) was significantly higher with ESL 1,200 mg (42.6%, p < 0.001) but not ESL 800 mg (30.5%, p = 0.07) than placebo (23.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs were dizziness, somnolence, nausea, headache, and diplopia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive oxcarbazepine: pooled efficacy
“Oxcarbazepine may increase the responder rate for 50% or greater reduction in seizure frequency compared to control treatment (RR 1.80, 95% CI 1.27 to 2.56; random-effects model; 6 studies; low-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment with oxcarbazepine was associated with an increased treatment withdrawal rate compared to control (RR 1.75, 95% CI 1.44 to 2.13; fixed-effect model; 6 studies; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive lamotrigine: pooled efficacy
“The overall risk ratio (RR) for 50% or greater reduction in seizure frequency was 1.80 (95% CI 1.45 to 2.23; 12 trials, 1322 participants (adults and children); moderate-certainty evidence)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lamotrigine as an add-on treatment for drug-resistant focal seizures appears to be effective in reducing seizure frequency, and seems to be fairly well-tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SV2A ligands
Mechanistic basis of the SV2A ligand class
“Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2 A (SV2A), whereas pregabalin and gabapentin are selective ligands for the α2δ1 subunits of the voltage-gated calcium channels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive levetiracetam: pooled efficacy and dose response
“RR was significantly in favour of levetiracetam compared to placebo when results were pooled across all doses (RR 2.37, 95% CI 2.02 to 2.78; 14 studies, 2455 participants; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose–response analysis demonstrated that the odds of achieving response (50% or greater reduction in seizure frequency) were increased by nearly 40% (odds ratio (OR) 1.39, 95% CI 1.23 to 1.58) for each 1000 mg increase in dose of levetiracetam.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive levetiracetam: pivotal placebo-controlled trial
Adjunctive levetiracetam: European multicentre trial
Adjunctive brivaracetam: pooled efficacy and withdrawal
“Participants receiving brivaracetam add-on were more likely to experience a 50% or greater reduction in seizure frequency than those receiving placebo (RR 1.81, 95% CI 1.53 to 2.14; 6 studies; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants receiving brivaracetam were more likely to attain seizure freedom; however, the evidence is of low certainty (RR 5.89, 95% CI 2.30 to 15.13; 6 studies).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, participants receiving brivaracetam did appear to be more likely to withdraw from treatment due to adverse events compared with those receiving placebo (RR 1.54, 95% CI 1.02 to 2.33; 6 studies; low-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive brivaracetam: phase 3 trial
“Percent reduction over PBO in 28-day adjusted seizure frequency (95% confidence interval [CI]) was 22.8% for BRV 100 mg/day (13.3-31.2%; p < 0.001) and 23.2% for BRV 200 mg/day (13.8-31.6%; p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The ≥ 50% responder rate (odds ratio vs. PBO; 95% CI) was 21.6% for PBO, 38.9% for BRV 100 mg/day (2.39; 1.6-3.6; p < 0.001), and 37.8% for BRV 200 mg/day (2.19; 1.5-3.3; p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive brivaracetam: pooled phase 3 analysis
“The ≥50% responder rate was 34.2% (50 mg/d, p = 0.0015), 39.5% (100 mg/d, p < 0.00001), and 37.8% (200 mg/d, p = 0.00003) vs 20.3% for placebo (p < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TEAEs in ≥5% patients taking BRV (vs placebo) were somnolence (15.2% vs 8.5%), dizziness (11.2% vs 7.2%), headache (9.6% vs 10.2%), and fatigue (8.7% vs 3.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Older broad-spectrum antiseizure medications
Position of valproate in the treatment sequence
Pregnancy prevention conditions for valproate and topiramate
Efficacy levels of older broad-spectrum agents as initial monotherapy
Adjunctive topiramate: pooled efficacy and withdrawal
“The RR for a 50% or greater reduction in seizure frequency with add-on topiramate compared to placebo was 2.71 (95% CI 2.05 to 3.59; 12 studies; high-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of participants achieving seizure freedom was also significantly increased with add-on topiramate compared to placebo (RR 3.67, 95% CI 1.79 to 7.54; 8 studies; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment withdrawal was significantly higher for add-on topiramate compared to placebo (RR 2.37, 95% CI 1.66 to 3.37; 12 studies; high-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive zonisamide: pooled efficacy and withdrawal
“The overall RR with 95% confidence interval (CI) for at least a 50% reduction in seizure frequency for 300 mg to 500 mg/day of zonisamide compared to placebo was 1.90 (95% CI 1.63 to 2.22; 7 trials, 1371 participants; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number needed to treat for an additional beneficial outcome was six (95% CI 4.1 to 6.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The RR for treatment withdrawal for 300 mg to 500 mg/day of zonisamide compared to placebo was 1.59 (95% CI 1.18 to 2.13; 6 trials, 1099 participants; moderate-certainty evidence)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Teratogenic risk restricting use
“Valproate, phenobarbital, and topiramate increase the risk of major congenital malformations in babies born to people with epilepsy and should therefore be avoided in those planning to conceive or who are pregnant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AMPA receptor antagonists
Perampanel in treatment-resistant adult focal epilepsy
Mechanism and approved role of perampanel
“Perampanel is a highly selective, non-competitive AMPA receptor antagonist that may exert its antiepileptic effect through selective inhibition of AMPA receptors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“as add-on treatment for people with focal epilepsy who are 12 years of age and older” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive perampanel: pooled efficacy and withdrawal
“Compared with placebo, participants receiving perampanel were more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.67, 95% CI 1.43 to 1.95; 7 trials, 2524 participants; high-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to placebo, perampanel increased seizure freedom (RR 2.50, 95% CI 1.38 to 4.54; 5 trials, 2323 participants; low-certainty evidence)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants treated with perampanel were more likely to withdraw from treatment due to adverse effects compared to those receiving placebo (RR 2.36, 95% CI 1.59 to 3.51; 7 trials, 2524 participants; low-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Add-on perampanel is effective at reducing seizure frequency and may be effective at maintaining seizure freedom for people with drug-resistant focal epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive perampanel: pivotal study 304
“Using this intent-to-treat population over the double-blind phase, the median percent change in seizure frequency was -21.0%, -26.3%, and -34.5% for placebo and perampanel 8 and 12 mg, respectively (p = 0.0261 and p = 0.0158 for 8 and 12 mg vs placebo, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty percent responder rates during the maintenance period were 26.4%, 37.6%, and 36.1%, respectively, for placebo, perampanel 8 mg, and perampanel 12 mg; these differences were not statistically significant for 8 mg (p = 0.0760) or 12 mg (p = 0.0914).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive perampanel: pivotal study 305
“The 50% responder rates (intent-to-treat analysis) were 14.7%, 33.3%, and 33.9%, respectively, for placebo, perampanel 8 mg, and perampanel 12 mg, with significant improvements over placebo for both perampanel 8 mg (p = 0.002) and 12 mg (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive perampanel: dose-ranging study 306
“Median percent change in seizure frequency-the primary efficacy endpoint-was -10.7%, -13.6%, -23.3%, and -30.8% for placebo, perampanel 2, 4, and 8 mg/day, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The corresponding 50% responder rates were 17.9%, 20.6%, 28.5%, and 34.9%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cenobamate
Position in the second-line add-on tier
Recommendation for use in drug-resistant focal onset seizures
Adjunctive cenobamate: pooled efficacy
“The overall RR for at least a 50% reduction in seizure frequency for add-on cenobamate at any dose compared to placebo was 2.17 (52% versus 24%, 95% CI 1.66 to 2.84; 2 studies, 605 participants; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The RR for seizure freedom for add-on cenobamate at any dose compared to placebo was 4.45 (16% versus 5%, 95% CI 2.25 to 8.78; 2 studies, 605 participants; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Add-on cenobamate is probably better than placebo in reducing the frequency of seizures by at least 50% and in achieving seizure freedom in adults with focal epilepsy uncontrolled by one or more concomitant ASMs (moderate level of certainty).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive cenobamate: pivotal placebo-controlled trial
“Compared to placebo, cenobamate conferred a greater median percent seizure reduction (55.6% vs 21.5%; p < 0.0001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The responder rate (≥50% reduction in seizure frequency) was 50.4% for cenobamate and 22.2% for placebo (p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During maintenance, 28.3% of cenobamate-treated and 8.8% of placebo-treated patients were seizure-free.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive cenobamate: dose-response trial
“Responder rates during the maintenance phase were 25% (26 of 102 patients) for the placebo group compared with 40% (41 of 102; odds ratio 1·97, 95% CI 1·08-3·56; p=0·0365) for the 100 mg dose group, 56% (55 of 98; 3·74, 2·06-6·80; p<0·0001) for the 200 mg dose group, and 64% (61 of 95; 5·24, 2·84-9·67; p<0·0001) for the 400 mg dose group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-emergent adverse events led to discontinuation in five (5%) patients in the placebo group, 11 (10%) in the 100 mg dose group, 15 (14%) in the 200 mg dose group, and 22 (20%) in the 400 mg dose group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One serious case of drug reaction with eosinophilia and systemic symptoms occurred in the 200 mg cenobamate group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive cenobamate: long-term open-label safety study
“The ≥50% responder rate for the total treatment duration was 71.7% (172/240).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among all patients who received a dose of cenobamate in the maintenance phase (n = 214), 13.1% (28/214) and 40.2% (86/214) achieved 100% and ≥90% seizure reduction during their entire maintenance treatment duration (median = 29.5 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Common treatment-emergent adverse events among all 240 patients included fatigue (34.6%), dizziness (32.1%), and somnolence (29.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of third-generation adjunctive antiseizure medications
“Sixteen trials (BRV: n = 3, CNB: n = 1, ESL: n = 4, LCM: n = 4, PER: n = 4) were included, overall enrolling 4507 patients randomised to add-on active treatments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cenobamate was associated with a higher rate of ≥ 50% seizure frequency reduction than BRV [odds ratio (OR) 2.02, 95% confidence interval (CI) 1.11–3.66], ESL (OR 1.93, 95% CI 1.07–3.48), LCM (OR 1.86, 95% CI 1.04–3.32), and PER (OR 2.07, 95% CI 1.16–3.70).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjunctive cenobamate had the greatest likelihood of being the best option for the ≥ 50% and 100% seizure frequency reduction. Adjunctive brivaracetam and lacosamide had the highest probabilities of being the best-tolerated treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of approved add-on antiseizure medications for focal epilepsy
“All ASMs showed significantly higher ≥50% responder rate compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among treatments, significantly higher 100% responder rate was observed with cenobamate compared to eslicarbazepine (10.71; 95% CI: 1.56–323.9) and zonisamide (10.63; 95% CI: 1.37–261.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the ASMs included, cenobamate had the greatest likelihood of allowing patients to attain seizure freedom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis ranking by seizure response and seizure freedom
“For seizure response, all ASMs were significantly superior to placebo, with RTG ranking highest, followed by CNB.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For seizure freedom, BRV was highest-ranked, followed by CNB, with BRV 100 mg/d leading, followed by CNB 400 mg/d.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert consensus on position in the treatment sequence
“Cenobamate can be used after the failure of two antiseizure medications, rather than being reserved for later stages of treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This manuscript aims to synthesize available clinical trial data, real-world studies, and expert opinions regarding the use of cenobamate, and to provide practical recommendations for its early introduction in patients with drug-resistant focal epilepsy, particularly following the failure of two adequately dosed ASMs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Alpha-2-Delta calcium channel ligands
Pregabalin in treatment-resistant adult focal epilepsy
Mechanistic basis of the alpha-2-delta ligand class
“Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2 A (SV2A), whereas pregabalin and gabapentin are selective ligands for the α2δ1 subunits of the voltage-gated calcium channels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive pregabalin: pooled efficacy
“For the primary outcome, participants randomised to pregabalin were significantly more likely to attain a 50% or greater reduction in seizure frequency compared to placebo (RR 1.95, 95% CI 1.40 to 2.72, 9 trials, 2663 participants, low-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pregabalin was significantly associated with seizure freedom (RR 3.94, 95% CI 1.50 to 10.37, 4 trials, 1125 participants, moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For people with drug-resistant focal epilepsy, pregabalin when used as an add-on treatment was significantly more effective than placebo at producing a 50% or greater seizure reduction and seizure freedom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GABAergic medications
Position in the third-line add-on tier
Vigabatrin and rufinamide in treatment-resistant focal epilepsy
“VGB and RFN should be considered established as effective for decreasing seizure frequency in TRAFE (Level A) but are not first-line agents (retinopathy risk with VGB and modest benefit with RFN).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clobazam and OXC-XR use may be considered to decrease seizure frequency in TRAFE (Level C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vigabatrin is not first-line in new-onset focal epilepsy
Adjunctive tiagabine: pooled efficacy and withdrawal
“The overall risk ratio (RR) with 95% confidence intervals (CIs) for a 50% or greater reduction in seizure frequency (tiagabine versus placebo) was 3.16 (95% CI 1.97 to 5.07; 3 trials; 769 participants; high-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The RR for treatment withdrawal (tiagabine versus placebo) was 1.81 (95% CI 1.25 to 2.62; 3 trials, 769 participants; moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tiagabine reduced seizure frequency but was associated with some adverse effects when used as an add-on treatment in people with drug-resistant focal epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vigabatrin: mechanism, vision loss, and restricted distribution
Epilepsy surgery
Referral for resective epilepsy surgery
Role and outcomes of resective surgery
“Epilepsy surgery is the treatment of choice for patients with drug-resistant seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Resective surgery can improve quality-of-life and cognitive outcomes and is the only treatment demonstrated to improve survival and reverse excess mortality attributed to drug-resistant epilepsy (DRE)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Yet, referral for surgical evaluations is often delayed while palliative options are pursued, with significant adverse consequences due to increased morbidity and mortality associated with intractable epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing of referral for surgical evaluation
“Referral for a surgical evaluation should be offered to every patient with drug-resistant epilepsy (up to 70 years of age), as soon as drug-resistance is ascertained, regardless of epilepsy duration, sex, socioeconomic status, seizure type, epilepsy type (including epileptic encephalopathies), localization, and comorbidities” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A surgical referral should be considered for older patients with drug-resistant epilepsy who have no surgical contraindication, and for patients (adults and children) who are seizure-free on 1–2 anti-seizure medications (ASM)s but have a brain lesion in non-eloquent cortex” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomized trial of surgery for temporal lobe epilepsy
“At one year, the cumulative proportion of patients who were free of seizures impairing awareness was 58 percent in the surgical group and 8 percent in the medical group (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In temporal-lobe epilepsy, surgery is superior to prolonged medical therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Four patients (10 percent) had adverse effects of surgery. One patient in the medical group died.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Randomized trial of early surgery in newly intractable temporal lobe epilepsy
“Zero of 23 participants in the medical group and 11 of 15 in the surgical group were seizure free during year 2 of follow-up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with newly intractable disabling MTLE, resective surgery plus AED treatment resulted in a lower probability of seizures during year 2 of follow-up than continued AED treatment alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients are typically referred for surgery after 20 years of seizures, often too late to avoid significant disability and premature death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Practice parameter on temporal lobe resection
“A single Class I study and 24 Class IV studies indicate that the benefits of anteromesial temporal lobe resection for disabling complex partial seizures is greater than continued treatment with antiepileptic drugs, and the risks are at least comparable.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For patients who are compromised by such seizures, referral to an epilepsy surgery center should be strongly considered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Laser interstitial thermal therapy for mesial temporal lobe epilepsy
“At both 1- and 2-years after LITT, 58.0% achieved Engel I outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LITT is a viable treatment for mTLE in patients who have been properly evaluated at a comprehensive epilepsy center.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurostimulation
Vagus nerve stimulation: guideline update on efficacy over time
“A ≥50% seizure reduction occurred in 36.8% of patients at 1 year, 43.2% at 2 years, and 42.7% at 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median seizure reductions relative to baseline were 35% at 1 year, 44.3% at 2 years, and 44.1% at 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“VNS may be considered progressively effective in patients over multiple years of exposure (Level C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adult patients receiving VNS for epilepsy, improvement in mood may be an additional benefit (Level C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vagus nerve stimulation: pivotal randomized trial
“Patients receiving high stimulation (94 patients, ages 13 to 54 years) had an average 28% reduction in total seizure frequency compared with a 15% reduction in the low stimulation group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Vagus nerve stimulation is an effective and safe adjunctive treatment for patients with refractory partial-onset seizures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Responsive neurostimulation: pivotal randomized trial
“Seizures were significantly reduced in the treatment (-37.9%, n = 97) compared to the sham group (-17.3%, n = 94; p = 0.012) during the blinded period and there was no difference between the treatment and sham groups in adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study provides Class I evidence that responsive cortical stimulation is effective in significantly reducing seizure frequency for 12 weeks in adults who have failed 2 or more antiepileptic medication trials, 3 or more seizures per month, and 1 or 2 seizure foci.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Responsive neurostimulation: nine-year prospective outcomes
“responder rate was 73%, and 35% had a ≥90% reduction in seizure frequency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found that 18.4% (47 of 256) experienced ≥1 year of seizure freedom, with 62% (29 of 47) seizure-free at the last follow-up and an average seizure-free period of 3.2 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no serious AEs related to stimulation, and the sudden unexplained death in epilepsy (SUDEP) rate was significantly lower than predefined comparators” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deep brain stimulation of the anterior nucleus of the thalamus: pivotal trial
“In the last month of the blinded phase the stimulated group had a 29% greater reduction in seizures compared with the control group, as estimated by a generalized estimating equations (GEE) model (p = 0.002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By 2 years, there was a 56% median percent reduction in seizure frequency; 54% of patients had a seizure reduction of at least 50%, and 14 patients were seizure-free for at least 6 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deep brain stimulation of the anterior nucleus of the thalamus: five-year follow-up
“The median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The responder rate (≥50% reduction in seizure frequency) at 1 year was 43%, and 68% at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the 5 years of follow-up, 16% of subjects were seizure-free for at least 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“anterior thalamic stimulation is associated with a 69% reduction in seizure frequency and a 34% serious device-related adverse event rate at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deep brain stimulation of the anterior nucleus of the thalamus: seven-year follow-up
“At 7 years, median seizure frequency percent reduction from baseline was 75% (p < .001), with no outcome differences related to prior vagus nerve stimulation or resective surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most severe seizure type, focal to bilateral tonic-clonic, was reduced by 71%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ketogenic dietary therapy
Ketogenic diet in drug-resistant epilepsy
Ketogenic diet in adults with intractable epilepsy: meta-analysis
“We identified 402 articles, of which, 16 studies including 338 patients met the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results of the meta-analysis showed that the combined efficacy rates of all the symptoms of seizure freedom, seizure reduction by 50% or more, and seizure reduction below 50% in adults with intractable epilepsy were 13%, 53%, and 27%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendations for ketogenic dietary therapy in adults
“Surveys were obtained from 20 medical institutions with >2,000 adult patients treated with KDTs for epilepsy or other neurologic disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“KDTs may be safe and effective in treating adults with drug-resistant epilepsy, and there is emerging evidence supporting the use in other adult neurologic disorders and general medical conditions as well.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Roughly one third of adults with epilepsy continue to have seizures despite available antiseizure medications. In a 30-year longitudinal cohort of participants with newly diagnosed epilepsy, 1,144 participants (63.7%) had been seizure free for the previous year or longer at the end of the study period, and the authors concluded that overall outcomes in newly diagnosed epilepsy have not improved despite the availability of many new medications with differing mechanisms of action. The yield of each successive medication falls steeply. Expressed as model-predicted probabilities, the first regimen gave a probability of seizure freedom of 50.5%, the second added 11.6%, the third added 4.1%, and from the fourth regimen onward each additional medication added approximately 1% or less. An earlier cohort in the same clinical setting reported that 222 of 470 previously untreated participants (47%) became seizure free on their first medication and 67 (14%) on a second or third, and that among participants with no response to the first medication only 11% subsequently became seizure free when the first failure was due to lack of efficacy, compared with 41% when it was due to intolerable side effects. A 2025 update reported that 64% of participants were seizure free, a proportion identical to that reported in the smaller 2000 study from the same setting.
Tolerability and interaction burden compound this efficacy ceiling. In up to a quarter of people, tolerability issues may lead to treatment discontinuation and harm adherence, and polypharmacotherapy further increases the risk of drug interactions and adverse events. Carbamazepine, phenobarbital, phenytoin, and primidone induce cytochrome P450 enzymes while valproic acid inhibits them, changing the serum concentrations of other antiseizure medications and of anticoagulants, oral contraceptives, antidepressants, antipsychotics, antimicrobial drugs, antineoplastic drugs, and immunosuppressants. Enzyme-inducing medications also affect sex hormone metabolism, vitamin D homeostasis, bone metabolism, and cholesterol synthesis, and reduce the effectiveness of hormonal contraceptives. Valproate, phenobarbital, and topiramate increase the risk of major congenital malformations, and in the United Kingdom valproate must not be prescribed to any woman or girl able to have children unless the conditions of the Pregnancy Prevention Programme are followed, because around 1 in 9 babies (11%) exposed in pregnancy will have a birth defect.
The only previously marketed potassium channel opener, ezogabine, also known as retigabine, is no longer available. Its United States label carried a warning that the product can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, restricted use to adults who had responded inadequately to several alternative treatments, and required baseline and six-monthly visual monitoring by an ophthalmic professional. Approximately 10% of participants in long-term clinical trials developed skin discoloration, generally after two or more years of treatment and at doses of 900 mg or greater, and retinal pigmentary abnormalities occurred in about one third of participants examined after approximately four years of treatment. The product was withdrawn from the United States market in 2017 after use declined, and the European Commission withdrew the marketing authorisation for Trobalt on 19 July 2018 at the request of the marketing authorisation holder, for commercial reasons.
Proportion of adults who remain uncontrolled on antiseizure medications
“At the end of the study period, 1144 patients (63.7%) had been seizure free for the previous year or longer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than one-third of patients experience epilepsy that remains uncontrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the availability of many new AEDs with differing mechanisms of action, overall outcomes in newly diagnosed epilepsy have not improved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the introduction of more than a dozen new AEDs in the past 2 decades, there remain no robust data to suggest improvement in treatment outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diminishing probability of seizure freedom with successive medication regimens
“There were 820 patients who were seizure free 1 year or longer with the initial AED, so the predicted probability was 50.5% (95% CI, 47.9%-53.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the first treatment failed, the second AED regimen only provided an additional 11.6% probability of seizure freedom (n = 208; 95% CI, 10.1%-13.1%; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the first 2 drugs failed to control all seizures, the third AED regimen offered only a 4.1% additional probability of seizure freedom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From the fourth AED regimen onwards, each additional AED only added an approximate 1% or less probability of seizure freedom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, our findings lend support to the definition of drug-resistant epilepsy as failure of 2 appropriately selected and tolerated AED regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early identification of refractory epilepsy
“More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy, but why this happens and whether it can be predicted are unknown.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 470 previously untreated patients, 222 (47 percent) became seizure-free during treatment with their first antiepileptic drug and 67 (14 percent) became seizure-free during treatment with a second or third drug.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who had no response to the first drug, the percentage who subsequently became seizure-free was smaller (11 percent) when treatment failure was due to lack of efficacy than when it was due to intolerable side effects (41 percent) or an idiosyncratic reaction (55 percent).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patterns of treatment response in newly diagnosed epilepsy
“The chance of seizure freedom declined with successive drug regimens, most markedly from the first to the third and among patients with localization-related epilepsies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 543 (49%) patients remained seizure-free on their first AED; 398 were treated with a second regimen (as monotherapy in 254, in combination with the first drug in 144), 146 (37%) of whom became seizure-free.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Less than 2% of patients became seizure-free on subsequent regimens but a few did so on their sixth or seventh regimen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seizure freedom unchanged across three decades of new antiseizure medications
“In this latest update, 64% of patients were seizure-free, a proportion identical to that reported in the earlier, smaller study undertaken in the same clinical setting and published in 2000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This lack of fundamental progress in treatment outcomes has underpinned the relentless search for the "magic bullet" that will result in long-term seizure freedom for the majority of people designated as having drug-resistant epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Goal of therapy and the proportion not achieving it
“The goal of epilepsy therapy is the complete elimination of seizures; however, this is not achievable in about one-third of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patient tolerability of adverse drug effects is integral to successful treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tolerability burden and polypharmacotherapy in focal seizures
“In up to a quarter of people, tolerability issues may lead to treatment discontinuation, as well as harming adherence” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“People with epilepsy are frequently treated with polypharmacotherapy, which further increases the risk of drug to drug interactions and, thus, adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enzyme induction and inhibition among antiseizure medications
“The older AEDs are susceptible to cause induction (carbamazepine, phenobarbital, phenytoin, primidone) or inhibition (valproic acid), resulting in a decrease or increase, respectively, in the serum concentration of other AEDs, as well as other drug classes (anticoagulants, oral contraceptives, antidepressants, antipsychotics, antimicrobal drugs, antineoplastic drugs, and immunosupressants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It should also be noted that enzyme-inducing AEDs affect endogenous biochemical pathways, as metabolism of sex hormones, vitamin D homeostasis and bone metabolism and cholesterol synthesis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contraceptive interactions and long-term adverse effects
Regulatory restrictions on valproate in people who can become pregnant
Ezogabine: warning, restricted indication, and monitoring requirement
Withdrawal of the only previously marketed potassium channel opener
“Ezogabine (retigabine), the first Kv7.2/3 activator introduced in 2011 for the treatment of focal seizures, was withdrawn from the market in 2017 due to declining use after discovery of its association with pigmentation changes in the retina, skin, and mucosae.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, retinal pigmentary abnormalities occurred in about one-third of patients who had eye examinations after approximately 4 years of treatment, but they may be seen earlier” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
European withdrawal of the retigabine marketing authorisation
Place in treatment, anticipated use, and care setting
Summary
The treatment position addressed by an adjunctive potassium channel opener is add-on therapy for adults whose focal onset seizures persist on existing antiseizure medications. Clinical practice guidance defines that position by the number of failed medications rather than by mechanism. The International League Against Epilepsy defines drug-resistant epilepsy as failure of adequate trials of two tolerated, appropriately chosen and used medication schedules, whether as monotherapy or in combination, to achieve sustained seizure freedom, and NICE adopts that definition. Approximately 30% of people with focal epilepsy have seizures that are not controlled by antiseizure medications. NICE directs that a single medication be used whenever possible, that an add-on treatment be considered when monotherapy is unsuccessful, and that when trials of add-on treatment do not reduce seizures the regimen chosen should be the one providing the best balance between effectiveness and tolerability.
Mechanistic diversity supports adding a new mechanism rather than a further agent from a class already used, since combining medications with various mechanisms of action appears more efficacious than combining medications sharing the same or comparable mechanisms. Expert consensus on the most recently approved adjunctive agent argues against reserving new mechanisms for late-stage use, recommending introduction after the failure of two adequately dosed antiseizure medications rather than at later stages of treatment. Azetukalner was studied in exactly this position: participants in X-TOLE2 had a median of five prior antiseizure medications, 51.3% were taking three concomitant medications, and approximately 40% were taking concomitant cenobamate.
The care setting is specialist outpatient neurology care with access to a tertiary or comprehensive epilepsy centre. NICE requires that all people with suspected or confirmed epilepsy have access to a tertiary epilepsy service via their specialist, and sets a four-week referral target when seizures are drug resistant or treatment causes intolerable side effects. The National Association of Epilepsy Centers recommends that all epilepsy centres regularly assess medication adherence and side effects as part of routine outpatient care, and regularly screen for drug-resistant epilepsy. Once-daily oral dosing with food, without titration and without dose adjustment of concomitant antiseizure medications, would place administration in the same setting as other oral adjunctive antiseizure medications.
Principles of monotherapy and add-on treatment
Rationale for combining medications with different mechanisms of action
Proportion of the focal epilepsy population that is drug resistant
“Drug-resistant focal epilepsy, as defined by the International League Against Epilepsy (ILAE), is characterized by the failure to achieve seizure control despite the use of at least two appropriately chosen and adequately dosed antiseizure medications (ASMs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This condition affects approximately 30% of patients and represents a significant clinical challenge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition of drug-resistant epilepsy used in guidance
Care setting: comprehensive epilepsy centres and outpatient monitoring
“As such, national and international professional organizations advocate for comprehensive epilepsy centers to provide both routine and highly specialized care for people with epilepsy (PWE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All epilepsy centers should regularly assess patient medication adherence and side effects as part of routine outpatient care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Access to a tertiary epilepsy service
Heterogeneity of treatment effect
Pretreatment seizure burden and early response as predictors
“Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of persistent seizures was higher in patients with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy (40 percent vs. 26 percent, P=0.004) and in patients who had had more than 20 seizures before starting treatment than in those who had had fewer (51 percent vs. 29 percent, P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Quantified effect of baseline seizure frequency and prior treatment failure
“For each increase in the numbers of seizures in the year prior to treatment, there was a 6% decrease in likelihood of being seizure free at the last clinic visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Epilepsy that was not successfully controlled with the first AED had 1.73 times greater odds of not responding to treatment for each subsequent medication regimen” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Course patterns and their predictability in newly diagnosed epilepsy
“Most patients with newly diagnosed epilepsy had a constant course which could usually be predicted early. The chance of seizure freedom declined with successive drug regimens, most markedly from the first to the third and among patients with localization-related epilepsies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcome pattern A was observed in 408 (37%), pattern B in 246 (22%), pattern C in 172 (16%), and pattern D in 272 (25%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This pattern of response was particularly impressive in patients with localization-related epilepsies, who should, therefore, be evaluated early for resective surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical predictors of pharmacoresistance
“Those reporting more than 10 seizures prior to initiation of therapy were more than twice as likely to develop refractory epilepsy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Univariate and multivariate logistic regression analyses demonstrated that pharmacoresistance was also associated with family history of epilepsy, previous febrile seizures, traumatic brain injury as the cause of the epilepsy, intermittent recreational drug use, and prior or current psychiatric comorbidity, particularly depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Factors not predicting poorer outcome included gender, neurological deficit and mental retardation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Structural etiology as a determinant of seizure control
“Seizure control (>1 year without seizure) was achieved in 82% of patients who had idiopathic generalized epilepsy, 35% of those with symptomatic partial epilepsy, 45% of those with cryptogenic partial epilepsy, and 11% of those with partial epilepsy associated with hippocampal sclerosis (HS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In partial epilepsy, HS, cerebral dysgenesis, and dual pathology (HS and another lesion) were associated with a low rate of seizure-free patients (11%, 24%, and 3%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacogenomic predictor of carbamazepine hypersensitivity
“HLA-B*15:02 is specific for carbamazepine- and oxcarbazepine-induced SJS and TEN, though the data are strongest for carbamazepine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The FDA label for carbamazepine carries a boxed warning about the risk of SJS/TEN with the presence of the HLA-B*15:02 allele” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive efficacy by number of previously used antiseizure medications
“Adjunctive BRV showed efficacy and was generally well tolerated in adults with focal seizures independent of the number of previous ASMs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 50% responder rate was 26.9%, 29.9%, 30.0%, and 29.7% for BRV 50, 100, 200, and 50-200 mg/day, respectively (placebo: 13.2%); odds ratios versus placebo were statistically significant (p < 0.05) for BRV 100, 200, and 50-200 mg/day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world seizure freedom by timing of adjunctive treatment
Azetukalner response by baseline disease severity
Care management intervention strategies
Adherence to antiseizure medications and interventions to improve it
“Poor adherence to antiepileptic medication is associated with increased mortality, morbidity and healthcare costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We included 20 studies reporting data on 2832 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Behavioural interventions such as intensive reminders and the use of mixed interventions demonstrate some positive results, however, we need more reliable evidence on their efficacy, derived from carefully-designed RCTs before we can draw a firm conclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consequences of nonadherence to antiseizure medications
“Nonadherence was associated with an over threefold increased risk of mortality compared to adherence (hazard ratio = 3.32, 95% CI = 3.11-3.54) after multivariate adjustments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Time periods of nonadherence were also associated with a significantly higher incidence of ED visits (IRR = 1.50, 95% CI = 1.49-1.52), hospital admissions (IRR = 1.86, 95% CI = 1.84-1.88), MVA injuries (IRR = 2.08, 95% CI = 1.81-2.39), and fractures (IRR = 1.21, 95% CI = 1.18-1.23) than periods of adherence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings suggest that nonadherence to antiepileptic drugs can have serious or fatal consequences for patients with epilepsy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Service models: specialist epilepsy nurses and self-management education
“Two intervention types, the specialist epilepsy nurse and self management education, have some evidence of benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At present it is not possible to advocate any single model of service provision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendations for specialized epilepsy centers
“The panel reached consensus on 52 recommendations covering services provided by specialized epilepsy centers in both the inpatient and outpatient settings” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All epilepsy centers should regularly screen patients for drug-resistant epilepsy and refer such patients to multidisciplinary surgical conference for consideration of epilepsy surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Telemedicine is an important resource, providing earlier access to specialized care and improving patient satisfaction, especially in resource-limited areas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Operational definition of seizure freedom
Clinically accepted benchmark used by the manufacturer
The responder endpoint used in adjunctive trials
Seizure freedom rather than seizure reduction drives quality of life
“In this study, HRQOL improvement occurred primarily among patients who achieved complete seizure freedom.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Many AED trials use a 50% seizure-frequency reduction criterion as a trial end point, but measurable impacts of this degree of reduction in seizure frequency on HRQOL in this sample were not observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No significant change in QOLIE-31 and QOLIE-89 overall scores was observed for subjects who did not achieve seizure freedom.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These results further support striving for seizure freedom as an epilepsy care goal.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical limitations of the 50 percent responder criterion
“We showed that individual variance in monthly seizure rates can lead to an unacceptably high false-positive rate in the detection of individual treatment responders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This finding suggests that some drugs may be incorrectly evaluated as effective; or, conversely, that helpful drugs could be rejected based on 50% response rates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote